Abstract
Biliary tract cancers (BTCs) include cholangiocarcinoma (intrahepatic (iCCA), hilar and distal), gallbladder and ampullary carcinoma (1) . BTCs are usually diagnosed in patients aged 50 to 70 years (2) and prognosis is poor (1, 3, 4) . Although considered rare(2), their incidence is increasing due to a clinically significant rise in diagnosis of iCCA (5) (6) (7) .
Systemic chemotherapy is the only treatment approach that demonstrated survival benefit in randomised phase III studies for advanced BTC (8, 9) . Cisplatin/gemcitabine is currently accepted as a reference first-line treatment in advanced BTC in many countries (8) based on the ABC-02 phase III clinical trial (10) . These findings were confirmed in a Japanese randomised phase II study (BT22 study) (11) with no quality of life detriment in the combination arm identified (12) . Other first-line chemotherapy options are under development (13) (14) (15) (16) . Role of second-line chemotherapy remains unclear (17) (18) (19) (20) (21) (22) , and suitable only for around 15% of patients due to rapidly-worsening performance status (19) .
Results of a randomised phase III study in this setting are awaited (23).
iCCA is considered a separate entity from other BTCs, due to anatomical and molecular characteristics (9) . iCCAs have been identified to express specific targetable genetic aberrations such as fibroblast growth factor receptor (FGFR) fusion rearrangements (9, (24) (25) (26) (27) (28) (29) and isocitrate dehydrogenase (IDH)-1 and-2 mutations (9, 30-33, 33, 34, 34-37) .
Patients with iCCA are more likely to have liver-only disease. For such scenarios, liver-directed therapies (LDT) are being explored (38) and suggested by some international guidelines (39). Methods of intra-arterial therapy include hepatic-arterial-embolisation, transarterial-chemo-embolisation, radio-embolisation (Yttrium This post-hoc analysis aimed to provide reference survival data to inform the design, sample size calculation and feasibility of future studies exploring the role of systemic (including targeted) therapies and LDT in advanced iCCA. Potential trial designs together with factors to consider in designing such studies are discussed.
Materials and methods

Study design
A post-hoc analysis of patient data collected as part of the prospective ABC-01 (48), -02 (10) and -03 (49) clinical trials was performed. These studies explored the role of first-line The primary aim of this analysis was to provide reference overall survival (OS) data of patients diagnosed with iCCA treated with first-line cisplatin/gemcitabine chemotherapy for future prospective studies. The sub-group of patients diagnosed with iCCA who were potentially eligible for LDT (defined as patients with liver-only disease) were analysed separately. Secondary objectives included progression-free survival (PFS); description of demographic data of patients diagnosed with iCCA; and assessment of the frequency of iCCA patients with liver-only disease. Suitability for LDT at 3 and 6 months required meeting the above-mentioned criteria for LDT, and being progression-free at 3 and 6 months following chemotherapy commencement, respectively.
Statistical analysis
All eligible patients were included in the analysis. All patients diagnosed with iCCA were included for a summary of baseline characteristics. For survival analysis, only patients treated with the combination of cisplatin/gemcitabine were included (current standard of care for good-performance status patients). Since the addition of cediranib to cisplatin/gemcitabine did not result in a statistically-significant impact on survival in the ABC-03 study (49), patients receiving both cediranib and placebo were included in the survival analysis of patients treated with cisplatin/gemcitabine. PFS and OS were measured as the time from randomisation to progression/death or death of any cause, respectively. Patients who did not experience a PFS or OS event were censored at the date of last follow-up. Calculations of PFS and OS using as a starting point 3 and 6 months from randomisation were performed to identify patients potentially suitable for LDT at 3 and 6 months, respectively. Survival analysis was performed with Kaplan-Meier method and Cox Regression (univariate and multivariable analysis including variables statistically significant in the univariate analysis (defined as p-value <0.05); Ph test was used to test for proportional-hazards assumption. For identification of prognostic factors, derived Hazard Ratio (HR), 95% confidence intervals (CI) and p-values were reported. Stata v.12 software was employed. P-values <0.05 were considered statistically significant. All statistical tests were two-sided. 
Results
Study population
Data from a total of 534 patients was retrieved (86, 324, and 124 patients from the ABC-01, ABC-02, and ABC-03 studies, respectively). Although the ABC-02 clinical trial reported a total of 410 patients, 86 were patients previously recruited into the ABC-01; such patients were included only once in this study. Thus, 324 patients from ABC-02 were eligible for this post-hoc analysis. Of the whole population of eligible BTC patients, 318 (59.6%) were Table 4 ). Table2 provides further PFS and OS rate information at different time-points explored for this patient population (data for additional time-points can be found in Supplementary Table 4) . No statistically significant differences in PFS (measured from study entry) were identified between liver-only iCCA (median = 8.4 95%CI =5.9-10.0) and non-iCCA BTC patients (median 7.9, 95%CI = 6.5-8.4; log rank pvalue = 0.37).
Prognostic factors
OS was shorter in patients diagnosed with iCCA and treated with cisplatin/gemcitabine, who had a higher serum carcinoembryonic antigen (CEA) levels at baseline. This factor was independent prognostic factor on multivariable analysis adjusted for other variables statistically significant in the univariate analysis (Table3).
Multivariable analysis confirmed that higher platelet count and high CEA at baseline were associated with shorter OS in the population of patients with iCCA treated with cisplatin/gemcitabine with liver-only disease (Table3). Although other factors were impacted on OS in the univariate analysis, none were independently prognostic in the multivariable analysis.
Discussion
There is an urgent need for additional therapies for patients with BTCs. Patients with iCCA represent a specific subgroup for whom novel targeted therapies and LDT are emerging as This study provides data on LDT-suitability (defined as presence of liver-only disease) and survival at different time-points (baseline, 3 months and 6 months), in order to explore which time-point would be more feasible to be explored. From the patient recruitment point of view, these results suggest that all three time-points would be adequate for introduction of LDT into patients' pathway; although there is a progressive drop in the number of eligible patients. OS increases progressively between these three groups, as can be expected due to an immortality bias (54). Due to the longer survival of the patient population who would be progression-free at 6 months from starting palliative chemotherapy (and therefore eligible for LDT at this point), a study incorporating LDT at this time-point would require prolonged follow-up with associated increased cost. (42, 55) . The presence of extra-hepatic disease, if low volume, is not necessarily required as an exclusion criteria (58). Most of these previously described prognostic factors, were not explored in the current analysis due to lack of available information, and should be considered at the time of RE study design. A strength of this work is the fact that all data had been previously produced and quality-assured as part of prospective clinical trials. This provides robustness to the results. In addition, a homogeneous population of patients treated with the same chemotherapy schedule is presented (treatment-naïve patients treated with first-line cisplatin/gemcitabine) and the same chemotherapy protocol for dose reductions and duration of chemotherapy.
Regarding the limitations of this post-hoc analysis, it is worth mentioning that the sample size was modest, since the analysis was focused on a small subpopulation of patients, which could have limited the survival analysis (particularly the Cox-regression for identification of prognostic factors when multiple covariates were included). Some patients had received cediranib as part of the ABC-03 study, but this was not expected to impact on the patients' outcomes (49). In addition, the actual percentage of patients suitable for LDT may have been under or overestimated due to the lack of information for assessing the above criteria, such as tumour spread pattern and technical problems (i.e. liver-lung shunt). In fact, only patients with liver-only disease were classified as suitable for LDT, excluding patients with liver-predominant disease.
In summary, the magnitude of benefit described in some of the studies focusing on iCCA is within the range that would be considered statistically significant if there was no knowledge of the survival of this patient cohort. This post-hoc analysis demonstrates that patients with iCCA have a better outcome than other patients with BTC and these survival figures should be considered at the time of future study design in this patient population. In addition, close to half of the patients diagnosed with iCCA are likely to have liver-only disease, and therefore may be suitable for approaches involving LDT. n/a n/a Hilar 57 (17.9) n/a n/a Not specified 30 (9.4) n/a n/a 
